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Polyamine-salt aggregates (PSA) are biomimetic soft-materials that have attracted great attention due to 
their straightforward fabrication methods, high drug-loading efficiencies and attractive properties for pH-
triggered release. Here, a simple and fast multicomponent self-assembly process was used to construct 
crosslinked poly(allylamine hydrochloride)/phosphate PSAs  (hydrodynamic diameter of 360 nm) 
containing glucose oxidase enzyme, as a glucose-responsive element, and human recombinant insulin, 
as a therapeutic agent for the treatment of diabetes mellitus (GI-PSA). The addition of increasing glucose 
concentrations promotes the release of insulin due to the disassembly of the GI-PSAs triggered by the 
catalytic in-situ formation of gluconic acid. While under normoglycemia, the GI-PSA integrity remained 
intact for at least 24 h, hyperglycemic conditions produced a 100% of cargo releasing after 4 h of glucose 
addition. This entirely supramolecular strategy presents great potential for the construction of smart 
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Rational and nature-inspired engineering of responsive delivery nanoarchitectures emerged as a 
fascinating challenge in materials science and modern biomedicine.[1–6] Within this context, the 
development of intelligent glucose-sensitive delivery devices to treat diabetes mellitus has prompted 
substantial research advances.[7–10] This metabolic disease is characterized by a deficit of endogenously 
produced insulin and/or insulin resistance that leads to elevated blood glucose levels (hyperglycemia).[11] 
Currently, diabetes mellitus affects more than 400 million people around the world, being one of the 
most serious threats to world public health.[12,13] In general, diabetic patients self-administer insulin with 
multiple subcutaneous injections to control blood glucose levels.[14–16] However, this methodology is 
usually painful and requires strict compliance on the part of the patient. In addition, open-loop 
subcutaneous administration of insulin often regulates inadequately the glucose levels, causing very 
severe disorders.[17–19] Therefore, several investigations have focused on the design of glucose-sensitive 
delivery systems with capacity to sense glucose levels and use this information to selectively activate the 
insulin release in hyperglycemia conditions (closed-loop insulin delivery).[18,20–22] Generally, to achieve 
the selective response, a glucose-responsive material is incorporated into the delivery platform, such as 
the glucose-oxidase enzyme (GOx).[23,24] GOx catalyzes the oxidation of D-glucose to gluconic acid, 
which in turn reduces the local pH.[25,26][27] In this way, the acidic pH can lead to conformational or 
structural changes in the delivery systems that ultimately drive the release of insulin.  
Glucose-sensitive materials with entrapped GOx have been increasingly studied employing 
architectures based on hydrogels, microgels and multilayer films[28–30], in which GOx is immobilized in 
complex macromolecular systems.[31] The use of tailorable polymeric (nano)particles offers attractive 
features for drug delivery systems, including suitable colloidal stability, large surface-volume ratios, high 
loading capacity, long circulation time in plasma and ability to cross biological membranes.[32–36] In this 
way, several self-regulated insulin delivery systems based on vesicles, micelles and nanogels have been 
presented.[37–42] Typically, these nanocarriers are formed by self-assembly or crosslinking of sensitive 
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and hinder the design scalability for practical applications. Therefore, the development of facile and 
robust engineering approaches to build innovative nanoscale platforms is an exciting challenge.   
In parallel, bioinspired polyamine-salt aggregates (PSA) based on the ionic crosslinking of 
polyamines have been intensively explored in the last decades for delivery of drugs, proteins, genes and 
medical imaging agents.[43,44] These soft materials have become a focus of attention mainly due to three 
crucial advantages: (1) their preparation involves a very simple one-step process based on the mixture of 
dilute polyelectrolyte solutions with multivalent salts under mild conditions;[45,46] (2) their three-
dimensional matrices present a great capacity to integrate different types of bioactive and functional 
compounds;[47–52] (3) they respond to external stimuli, such as pH and ionic strength, because the 
supramolecular network is essentially stabilized by electrostatic interactions.[53–56] Within this 
framework, poly (allylamine hydrochloride) (PAH) was used as a building block to generate PSA by 
crosslinking with simple inorganic phosphate (Pi).[57,58] 
In this sense, PAH/Pi PSA have been used to encapsulate functional compounds such as 
indocyanine green (ICG) and curcumin.[59–61]  Moya and co-workers also used a PAH/Pi PSA as a 
nanocarrier for pH-triggered release of small interfering RNA (siRNA).[62] They found that the PSA 
loaded with siRNA remains stable at physiological pH, and releases its cargo in acidic endosomes, where 
the protonation of the phosphate groups destabilize the electrostatic interactions that support the ionically 
crosslinked matrix. Very recently, we explored the physicochemical properties and the pH/ionic strength 
response of PAH/Pi PSA in solution phase.[63] We also used PSAs loaded with a model molecular dye as 
building blocks for the construction of  multilayer films with attractive properties for pH-controlled 
release.[64]  
In the present work, we show for the first time the co-immobilization and rational integration of 
proteins in the crosslinked PAH/Pi PSA. In particular, we pursue the goal of integrating both GOx and 
insulin into the ionically crosslinked PAH/Pi matrix to obtain a new kind of glucose-responsive soft 
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simple preparation process and that the resulting supramolecular nanocarriers present interesting 
properties for glucose-regulated insulin delivery. 
 
Materials and methods 
 
Chemicals: 
Poly(allylamine hydrochloride) (PAH) (Mw~17500), glucose oxidase (GOx) from Aspergillus 
niger (type VII), insulin human recombinant (Ins) (SAFC, 91077C) and 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES) were purchased from Sigma Aldrich. Sodium phosphate monobasic 
monohydrate (Pi) was purchased from Cicarelli. D-(+)-glucose (Glu), sodium hydroxide and 
hydrochloric acid were purchased from Anedra. All chemicals were used without further purification. 
 
GOx-Insulin-containing polyamine-salt aggregate (GI-PSA) assembly: 
In order to obtain 10 mL of a GI-PSA colloidal dispersion, we consecutively mixed the following 
solutions in a 50 mL beaker under constant stirring (50 rpm): 1) 2.34 mL of PAH (20 mM, monomer 
concentration), 2) 22.1 mL of HEPES buffer (20 mM, pH=7.4), 3) 1.95 mL of GOx (2 mg mL-1), 4) 1.95 
mL of Ins (2 mg mL-1) and 5) 1.731 mL of Pi (10 mM). All solutions (PAH, GOx, Ins, and Pi) were 
freshly prepared using a 20 mM aqueous solution of HEPES buffer as solvent and their pH values were 
adjusted to 7.4 using 1 M HCl or 1 M NaOH prior to mixing. We added each solution very quickly into 
the beaker to avoid heterogeneous reactions and waited 5 min between the addition steps. After the 
incorporation of Pi, 30 mL of a cloudy solution was obtained (0.13 mg mL-1 Ins, 0.13 mg mL-1 GOx, 
1.56 mM PAH and 0.577 mM Pi). The as-prepared colloidal dispersion was allowed to stabilize for 2 h 
under stirring to complete the crosslinking process. The dispersion was then centrifuged at 4000 rpm 
(RCF=1310 g) for 30 min and the supernatant was discarded to remove the excess of reactants (UV-Vis 
analysis of polypeptide content in the supernatant is shown in the Supporting Information, Figure S1). 
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ultrasonication for 15 min to yield 10 mL of GI-PSA colloidal dispersion. The resuspended dispersion 
was used for pH and glucose-triggered disassembly experiments. 
 
GI-PSA disassembly by external pH changes: 
The turbidity of the GI-PSA colloidal dispersion was tested at different pH values by measuring 
the transmittance percentage (%T) at λ=580 nm (light-scattering effects). To study the disassembly 
process, 50 mM HCl was added in small aliquots (0.5 - 2 µl) to 2 mL of GI-PSA colloidal dispersion 
while measuring pH and %T. A clear solution (100 %T) indicated total GI-PSA disassembly.  
 
GI-PSA disassembly by glucose addition: 
For glucose-induced disassembly studies, 2 mL of GI-PSA colloidal dispersion was placed in a 
plastic cuvette and thermostatized at 37 ºC. A small volume of glucose 0.5 M in 20 mM HEPES buffer 
(pH=7.4) was added into the cuvette and a chronometer was turned on. The solution was gently air-
injected every 20 minutes and both the pH and %T at λ=580 nm were registered, keeping the temperature 
stable at 37 ºC. pH values were registered using a capilar pH-electrode connected to an ADWA AD8000 
pH-meter. 
 
Dynamic light scattering (DLS) measurements: 
DLS measurements were carried out using a ZetaSizer Nano (ZEN3600, Malvern, U.K.) at 37 °C 
employing DTS1060 disposable cuvettes. The detector was placed at 173° backscatter angle and all 
measurements were conducted using 10 runs of 20 s. 
 
Transmission electron microscope (TEM) measurements: 
TEM images were obtained using a JEOL microscope (120 kV) equipped with a Gatan US1000 
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PSA transference to the grids was achieved by forming a meniscus between the grid (top) and a 
concentrated GI-PSA colloidal dispersion (bottom) for a few seconds, followed by air-drying. 
 
Circular dichroism (CD) spectroscopy measurements: 
 CD measurements were performed using a Jasco (Tokyo, Japan) J-815 CD spectrometer at 20 °C. 
A quartz cuvette with a 1-mm path length was used for the peptide region (200 – 250 nm). Each spectrum 
is the result of the averaging of 5 consecutive scans. PSA sample contained 0.13 mg mL-1 GOx, 1.56 
mM PAH and 0.577 mM Pi in 20 mM HEPES buffer at pH=7.4. Free GOx sample contained 0.13 mg 
mL-1 GOx in 20 mM HEPES buffer at pH=7.4. 
 
Transmittance (%T) measurements: 
The transmittance of GI-PSA colloidal dispersions was measured using an Ocean Optics DH-2000 
at λ=580 nm with 1-cm light-path plastic cuvettes.  
 
UV-Visible spectroscopy measurements: 
UV-Visible experiments were carried out using a Perkin Elmer Lambda 35 spectrometer and a 2-
mm light-path quartz cuvette. 
Results and Discussion 
GI-PSA characterization and pH-triggered disassembly: 
 
By a simple combination of the individual building blocks under mild conditions (room 
temperature, neutral pH, atmospheric pressure, and aqueous solution), we constructed a PAH/Pi 
polyamine-salt aggregate (PSA) that contains glucose oxidase and human recombinant insulin (GI-PSA) 
(Scheme 1). At pH=7.4, the negative net charge of these two proteins allows for their integration into the 
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the PAH/Pi PSA assembly is the HPO42- anion, which strongly interacts with the positively charged 
amine groups in PAH chains [63].  
 
Scheme 1. GI-PSA formation at neutral pH. PAH crosslinking with phosphate anions and co-
encapsulation of glucose oxidase (GOx, violet spheres) and insulin (Ins, blue spheres). 
Figure 1a shows the size distribution of GI-PSAs obtained from dynamic light-scattering (DLS) 
measurements at 37 °C (pH=7.4). A single peak centered at 360 nm with a polydispersity index of 0.1 
indicates a narrow and homogeneous distribution of sizes in the solution phase. This result is consistent 
with the hypothesis that the crosslinking of PAH occurs concomitantly with the uptake of insulin and 
GOx. On the other hand, the TEM image in Figure 1b shows that GI-PSAs have a spherical shape and a 
wide distribution of particle diameters with a maximum at 90 nm and a tail at large diameter. The fact 
that TEM sizes are smaller than DLS ones is probably due to dehydration of the sample for TEM 
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Figure 1. GI-PSA size distribution obtained by DLS (a) and TEM (b) analysis. Inset shows a TEM image 
of a GI-PSA sample. 
We tested the stability of GI-PSAs over time in order to evaluate the possibility of non-selective 
undesired release of proteins. For this purpose, after 24 h of assembly, the sample was centrifuged, and 
the supernatant was analyzed by UV-Vis spectroscopy. Both GOx and insulin have absorption bands 
around 275 nm due to the presence of tryptophan or tyrosine residues.[65,66] In addition, GOx exhibits 
absorption bands at 375 nm and 450 nm that are characteristic of the flavin adenine dinucleotide cofactor 
bound to the protein structure.[67] The spectrum of the supernatant showed a much smaller absorption in 
the UV and visible regions than a solution containing only GOx and Insulin at the same final 
concentration of the colloidal sample (0.39 mg mL-1). This result indicates that the protein cargo is 
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that undesired protein release does not occurs (Figure S2). This result is not trivial, since it shows that it 
is possible to rationally integrate two functional proteins in PAH/Pi PSAs through a simple protocol and 
using only supramolecular interactions. Previously, Anderson and co-workers reported the development 
of glucose-responsive microgels based on a physically crosslinked matrix of chitosan/tripolyphosphate 
loaded with insulin.[28] However, in that example, the GOx enzyme had to be first covalently encapsulated 
in nanocapsules, and then incorporated into the microgels. 
The secondary structure of the GOx encapsulated in PSA was studied by CD spectroscopy. Figure 
S3 shows the far-UV CD spectra of free and encapsulated GOx in HEPES buffer at pH=7.4. The CD 
spectrum of native GOx exhibited two negative minima in the ultraviolet region around at 207 and 220 
nm, which are characteristic of an α-helical conformation.[68–71] GOx within PSA also present a negative 
shift in the CD signal similar to that observed for the free enzyme, revealing a permanence of the helix 
conformation. However, the CD band at 207 nm lowers its intensity in a 60%. This could indicate a 
decrease in the α-helical content and changes in the secondary structure of the enzyme due interactions 
with polyamine chains. 
As we previously reported, a PAH/Pi crosslinked colloid can be disassembled by altering the pH 
of the solution.[63]  At low ionic strength conditions, if the pH is below 5.5, the HPO42- anions that act as 
GI-PSA crosslinker get protonated completely forming the H2PO41- ions. As this monovalent anion is not 
able to act as a crosslinking agent, the complete dissolution of the GI-PSAs is produced. On the other 
hand, if the pH is raised above 9.7, the amine groups in PAH get deprotonated and the GI-PSAs also 
dissolve. This behavior represents one of the key features of GI-PSAs as can be used for pH-triggered 
release of therapeutic drugs.[43,44,72] 
The integrity of GI-PSAs was evaluated as a function of the pH by measuring the light scattering 
of a GI-PSA colloidal dispersion at different pH values. For this purpose, we measured the transmittance 
of the sample at λ=580 nm while lowering the pH by adding small aliquots of HCl. Light extinction at 













Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
decrease of either the number or the mean size of GI-PSA particles. Figure 2a shows the transmittance 
at λ=580 nm between pH=7.4 and pH=4. A slow increase in the transmittance is detected until pH=5.25 
and, after this point, a marked increase is observed reaching 50% of transmittance at pH=5.1, and 100% 
at pH=4.8. Figure 2b shows two photographs of the sample before and after disassembly. In the latter, a 
translucent solution indicates quantitative dissolution of GI-PSA colloids by addition of acid. The critical 
pH required to dissolve the colloids is lower in the present system than in an analog system without 
insulin and GOx.[63] This extra-stabilization produced by the addition of the proteins can be attributed to 
the electrostatic coupling between the negatively charged insulin/GOx macromolecules (pIinsulin=5.3 ; 
pIGOx=4.2) and the protonated PAH chains.[65,73,74] In other words, the proteins also act as crosslinking 
agents together with the phosphate anions. 
 
 
Figure 2. a) Total transmittance at λ=580 nm for a GI-PSA colloidal dispersion vs. pH. The pH was 
externally adjusted by addition of HCl. b) Photographs of the GI-PSA colloidal dispersion at pH=7.4 
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Glucose-triggered GI-PSA disassembly: 
GOx enzyme catalyzes the oxidation of glucose by dissolved molecular oxygen.[25,75] The products 
of the reaction are D-glucono-δ-lactone and hydrogen peroxide. In a following reaction step, the D-
glucono-δ-lactone hydrolyzes to gluconic acid (pKa=3.86). Thus, at pH values higher than the pKa of 
gluconic acid, the oxidation of glucose concomitantly releases protons that lower the pH of the solution. 
In this way, the oxidation of glucose catalyzed by the GOx loaded into the GI-PSA is expected to dissolve 
the colloids by indirect shifting of the solution pH. 
In order to evaluate the glucose responsiveness, GI-PSAs were incubated at 37°C in solutions with 
different glucose concentrations, including hyperglycemic levels (10, 15 and 20 mM),[76] a 
normoglycemic level of 5 mM,[77] and a control level of 0 mM. We recorded the time variation of the pH 
and %T immediately after the addition of glucose (see Figure 3a and 3b, respectively). The results show 
that the pH drops over time and the rate of pH change increases with increasing glucose level. This 
behavior reveals that GOx, immobilized in the ionic matrix, preserves its catalytic capabilities. On the 
other hand, under conditions of normoglycemia (5 mM), the pH reaches a constant value of 6.75 after 4 
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Figure 3. Time evolution of GI-PSAs after addition of 0 mM, 5 mM, 10 mM, 15 mM and 20 mM glucose: 
(a) pH vs. time (b) transmittance at λ=580 nm vs. time. Simplified representation of GI-PSA stability in 
normoglycemia (c) and hyperglycemia (d).  
The time variation of the sample transmittance (Figure 3b) shows a marked increase for the cases 
of 20 and 15 mM glucose concentration, reaching %T = 100% after 4 and 5 h, respectively. This result 
indicates that the total dissolution of GI-PSAs is achieved under hyperglycemic conditions (Figure 3d), 
releasing the total content of protein into the media. The complex evolution of the pH over time observed 
in Figure 3a can be numerically simulated considering the acid/base equilibria of the different 
components in the solution and the typical Michaelis-Menten kinetics of the enzyme. Figure S4 shows 
that both experimental and theoretical curves follows the same sigmoidal shape, demonstrating that the 
changes in the solution pH can be explained in terms of a combination between the rate of gluconic acid 
production by GOx and the different degree of acid and buffer dissociation. A detailed description of the 
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information. For both 15 and 20 mM samples, the total GI-PSA disassembly is produced when the pH 
reaches a critical value of 4.5 (Figure 3a), similar to the dissolution pH obtained in the pH-forced 
disassembly experiment (Figure 2a). This result is consistent with the hypothesis that the dissolution of 
GI-PSAs is produced by the partial protonation of HPO42- and the consequent loss of its crosslinking 
properties. This result has great significance as it proves that the release of insulin can be indirectly 
triggered by increasing glucose concentration.  
While in the case of 10 mM glucose concentration, a constant increase in the transmittance is 
detected during 7 h, in conditions of normoglycemia (5 mM) the transmittance linearly increase for the 
first 3.5 h and finally reaches a stable value of 26% that remains constant over 2 days at 37°C (not shown). 
After this period of time, the sample (5 mM) was analyzed by DLS obtaining a homogeneous distribution 
of particle sizes with a maximum centered at a diameter of 400 nm (Figure S5 b), similar to the case of 
a freshly prepared GI-PSA colloidal suspension (Figure 1a). This observation indicates that, if the pH is 
high enough (pH=6.75), the GI-PSAs remain stable in solution due to the presence of HPO42- anions 
acting as crosslinking agents (Figure 3c). 
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Figure 4 shows the GI-PSA response time (defined as the time at which the colloidal suspension 
reaches 50% transmittance at λ=580 nm) as a function of the concentration of added glucose. The 
obtained data indicate that the disassembly kinetics of GI-PSAs can be easily modulated by changing the 
glucose concentration. Also, the GI-PSA disassembly time decreases considerably as the glucose 
concentration increases until reaching a constant value around 1.5 h for glucose levels higher than 30 
mM. The Michaelis constant for GOx with glucose is around 20 mM,[75] which indicates that the 
appearance of the plateau in Figure 4 is probably caused by the saturation of the enzyme at high glucose 
concentration. 
Finally, we evaluated the glucose-triggered insulin release. The percentage of total protein (GOx + 
insulin) released was measured after 48 h of GI-PSA incubation with different concentrations of glucose 
(Figure 5). For this propose, each GI-PSA colloidal suspension was centrifuged, and the corresponding 
supernatants were analyzed by UV-Vis spectroscopy (Figure 5a). The total protein content, referred as 
100 %, was obtained by analyzing the UV-Vis spectrum at λ=275 nm of a GI-PSA solution after complete 
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Figure 5. a) UV-visible spectra of centrifuged GI-PSA supernatant 48 h after glucose addition and b) 
percentage of total protein released (GOx + Insulin) into the solution by spectral analysis at λ=275 nm. 
Figure 5b shows that, in the absence of glucose, the release of proteins from GI-PSAs was 9%. 
This small value indicates that the system has a suitable stability and keeps its cargo trapped after 48 
hours of preparation. In normoglycemia conditions (5 mM of glucose), a small release of around 15% of 
the total trapped protein was found, which is in congruence with the minor changes of pH and 
transmittance as a function of time observed in Figure 3. In addition, this observation is in line with the 
homogeneous distribution of the particle sizes found by DLS after 48 h of incubation (Figure S5). When 
the GI-PSAs were exposed to hyperglycemia conditions, the amount of released protein grew 
considerably, reaching a 100% for the cases of 15 and 20 mM glucose, in accordance with the complete 
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polypeptide was released, which indicates that the 60% remained linked to the GI-PSA structure after 48 
h. The change of the amount of released protein with the glucose concentration indicates that our 
nanocarrier has the ability to self-regulate the insulin release rate and fraction depending on the 
concentration of glucose in the media. 
 
Conclusions 
In summary, a new insulin delivery approach has been proposed based on the co-immobilization 
of GOx and insulin into a biomimetic polyamine-salt aggregate. This straightforward engineering route 
leads to the successful construction of entirely supramolecular spherical nanocarriers by simple mixing 
the subunits in mild conditions. 
The GI-PSA obtained in this work has the capacity to sense glucose levels and respond by 
activating the release of insulin. Under hyperglycemic conditions, the GOx trapped in the GI-PSA 
colloids converts glucose to gluconic acid, which results in an acidic environment that triggers the 
dissociation of the ionic pairs in the supramolecular structure and, consequently, promotes the insulin 
release. In contrast, negligible insulin release was observed under normoglycemia conditions. 
We believe this PSAs-based non-covalent strategy has great potential for the generation of an 
efficient and robust glucose-responsive insulin delivery system. In order to adjust the system to operate 
in physiological conditions, further studies must be carried out checking the GI-PSA stability over time 
under in vivo conditions for different glucose levels and GOx contents. The main challenge in the 
application of glucose-responsive systems is to achieve a rapid response rate in physiological 
environment with highly regulated pH. In this sense, it is essential that the glucose-responsiveness under 
hyperglycemia conditions generates a fast change of local pH that overcomes the physiological regulation 
and activates the selective release of insulin. Although direct comparison with other GOx-based 
platforms is difficult due to the different experimental conditions used in each case, under in 
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to that observed for our system.[1–3] Interestingly, some of these systems were explored in vivo by 
subcutaneous administration in 3D-gels-based configurations and showed great ability to regulate blood 
glucose concentrations.[4–6] Thus, a future challenge for the implementation of PSA as an effective on-
demand insulin-releasing agent could be the development of semi-permeable PSA shells that allow 
significant local pH changes despite the body's natural pH regulation.  
 
Finally, it is worth highlighting that the successful co-immobilization of two biomacromolecules, 
as GOx and insulin, opens the possibility of exploring the encapsulation and hierarchical combination 
of other therapeutic and functional agents into the polyamine/phosphate PSAs, as well as the possibility 
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